Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-18T22:17:13.644Z Has data issue: false hasContentIssue false
  • English
  • Français

PL03-01 - Recent developments in the treatment of schizophrenia

Published online by Cambridge University Press:  17 April 2020

C. Höschl
C. Höschl*
Affiliation:
Prague Psychiatric Center and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic 1st Department of Psychiatry, Medical Faculty, University of Pavel Josef Safarik, Kosice, Slovak Republic

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The classical antipsychotic drugs exert primarily antidopaminergic properties, which are responsible also for their side-effects such as hyperprolactinemia and extrapyramidal syndrome. Nevertheless, psychotogenic pathways in the brain involve several different mechanisms, which could serve as targets of antipsychotic modalities, e.g., facilitation of glutamatergic and cholinergic neurotransmission, blockade of serotonin 5-HT2 receptors, expression of BDNF and bcl2, inhibition of GSK-3β phosphorylation and thus apoptosis etc.[1] Recent naturalistic trials brought updated experience with regard to efficacy, effectiveness and side-effect profile of antipsychotics and the comparison of antipsychotics of the first and second generation. In addition, recent developments in the treatment of schizophrenia involved also psychoeducation[2] and so called ITAREPS (Information Technology Assisted Relapse Prevention in Schizophrenia)[3], which improve adherence to treatment and therefore decrease significantly the relapse rate.

Type
Update on Session
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E205
Copyright
Copyright © European Psychiatric Association 2010

References

Horáček, J., Bubeníková-Valešová, V., Kopeček, M., Páleníček, T., Dockery, C., Mohr, P., Höschl, C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. Drugs 2006; 5: 389–40920Google Scholar
Motlova, L., Dragomirecka, E., Spaniel, F., Goppoldova, E., Zalesky, R., Selepova, P., Figlova, Z., Höschl, C. Relapse prevention in schizophrenia: does group family psychoeducation matter? One-year prospective follow-up field study. Int J Psychiat Clin Pract 2006; 10(1): 38–44Google Scholar
Spaniel, F., Vohlídka, P., Kožený, J., Novák, T., Hrdlička, J., Motlová, L., Cermák, J., Höschl, C. The Information Technology Aided Relapse Prevention Programme in Schizophrenia:an extension of a mirror-design follow-up. Int J Clin Pract 2008; 12: 1943–194662Google Scholar
Submit a response

Comments

No Comments have been published for this article.